10-Q quarterly report · filed Nov 9, 2026

Compass Therapeutics, Inc. (CMPX) Q3 2026 10-Q Quarterly Report

Short answer

Compass Therapeutics, Inc. (CMPX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$27M
−90.6% YoY · −8.0% QoQ
EPS (diluted)
−$0.15
−87.5% YoY · −15.4% QoQ

Source: XBRL data from the Compass Therapeutics, Inc. (CMPX) Q3 2026 10-Q on SEC EDGAR. USD.

Compass Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales generated
  • Operating margin -107.0% vs -110.9% YoY, based on operating losses of $28.8 million and $15.8 million
  • Tovecimig highest R&D spending, $14.4 million vs $3.3 million YoY
  • Cash, equivalents and marketable securities $163 million, funding operations into 2028
  • Operating cash use $48.3 million, up from $35.9 million YoY; FDA recommended survival-benefit trial before tovecimig BLA

Risk Factors

  • New corporate-governance risk: bylaws adopted exclusive Delaware and Massachusetts forums for specified stockholder litigation
  • Regulatory and legal risk: Securities Act claims restricted to U.S. District Courts in Delaware or Massachusetts
  • Macroeconomic risk: July 2026 U.S. tariffs of approximately 10% to 12.5% increased potential research and development costs
  • Operational risk: macroeconomic disruptions could delay clinical-trial initiation or expansion and material supply availability
  • Financial risk: deteriorating equity and credit markets could make future financing costlier, more dilutive, or unavailable

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Compass Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.